Animal Vaccines Market by Product (Inactivated Vaccines, Live Attenuated Vaccines, mRNA Vaccines), Animal Type (Companion Animals, Livestock Animals), Disease Type, Route of Administration, Distribution Channel - Global Forecast 2025-2032
Description
The Animal Vaccines Market was valued at USD 13.69 billion in 2024 and is projected to grow to USD 14.58 billion in 2025, with a CAGR of 6.93%, reaching USD 23.40 billion by 2032.
A strategic introductory overview of evolving scientific advances, regulatory pressures, and commercialization imperatives shaping the animal vaccines ecosystem
The animal vaccines sector is at an inflection point driven by converging scientific progress, shifting animal health priorities, and evolving distribution channels. Advances in molecular biology and platform technologies are expanding the vaccine toolbox, while heightened attention to zoonotic risk and antimicrobial stewardship intensifies demand for preventive solutions. Investors, manufacturers, and veterinary stakeholders face a more complex landscape in which scientific feasibility, regulatory pathways, and supply chain robustness all influence product success.
Against this backdrop, decisions about pipeline prioritization and resource allocation require a clear view of where innovation is translating into adoption. Breakthroughs in nucleic acid technologies, recombinant antigen design, and adjuvant optimization are enabling faster development cycles and more targeted protection across companion and production species. At the same time, regulatory frameworks and animal owner willingness to pay differ by jurisdiction, creating differentiated commercialization pathways.
This report frames those dynamics, connecting scientific innovation to practical imperatives for commercialization. It emphasizes how integrated thinking across R&D, manufacturing, and distribution can shorten time-to-adoption and strengthen resilience to regulatory and trade disruptions. By clarifying these linkages, leaders can better align investments with the realities of a rapidly evolving animal health ecosystem.
How platform technologies, supply chain modernization, and regulatory adaptation are jointly accelerating innovation and market entry across the animal vaccines landscape
The past several years have produced transformative shifts that are redefining how animal vaccines are developed, manufactured, and delivered. Platform technologies such as mRNA and recombinant expression systems have reduced biological complexity for certain targets, enabling more agile responses to emergent viral threats and allowing developers to pursue antigen designs that were previously impractical. These scientific shifts are complemented by advances in adjuvant chemistry and delivery systems that improve durability of immune responses, especially in production animals where long-term protection drives economic value.
Simultaneously, the industry has seen a marked movement toward integrated supply chains and regional manufacturing hubs to mitigate logistical risk and reduce time-to-deployment. Digital tools for cold chain monitoring, remote veterinary diagnostics, and data-driven disease surveillance are improving vaccine targeting and post-marketing evidence generation. Regulatory pathways are adapting to novel modalities, with agencies increasingly open to platform-based review paradigms that can accelerate approval for subsequent constructs built on validated platforms.
Taken together, these trends are catalyzing a shift from incremental product updates to platform-centric strategies. Organizations that combine scientific depth with operational flexibility and strong regulatory engagement are positioned to capture the most value as adoption patterns evolve across companion and production animal segments.
Assessment of how 2025 tariff adjustments have reshaped sourcing decisions, regional manufacturing strategies, and commercial resilience across the value chain
The cumulative effect of trade policy changes implemented in 2025 has rippled across sourcing, pricing, and distribution choices for animal vaccine stakeholders. Tariff increases and adjustments to import classifications have raised the cost and complexity of importing finished biologics and certain raw materials, prompting many manufacturers to reassess cross-border supply strategies. In response, companies have accelerated regional sourcing, relocated critical component manufacturing closer to end markets, and expanded local fill/finish capabilities to preserve margin and ensure timely delivery.
These adaptations have also altered procurement strategies among distributors and veterinary providers. Buyers are placing greater emphasis on vendor diversification and contractual terms that protect against sudden cost escalation. In parallel, some firms are renegotiating supply agreements with raw material suppliers and contract manufacturing organizations to share risk and secure priority access to limited capacity. The combination of tariff-driven cost pressures and supply chain reconfiguration has elevated the strategic importance of manufacturing redundancy, inventory planning, and tariff-aware route-to-market designs.
Looking forward, stakeholders that proactively map tariff exposure across the product lifecycle, invest in regional manufacturing nodes where feasible, and cultivate flexible logistics options will be better positioned to maintain continuity of supply and protect commercial margins amid ongoing policy uncertainty.
In-depth segmentation analysis showing how product modalities, species-specific needs, disease targets, administration routes, and distribution channels interact to shape strategic choices
A granular segmentation lens reveals how product modality, animal species, disease target, administration route, and distribution channel each shape research priorities and commercial opportunity. Product innovation spans inactivated vaccines, live attenuated vaccines, mRNA vaccines, recombinant vaccines, and subunit vaccines, with modality choice influenced by pathogen biology, safety profile, and manufacturing scalability. Species differences matter: companion animal markets center on cats and dogs where owner willingness to invest in advanced modalities and convenience-driven formats is relatively high, while livestock markets focus on cattle, poultry, sheep, and swine where economic drivers and mass-administration logistics dominate adoption decisions.
Disease-specific targeting further refines strategy; bacterial infections such as clostridial disease, E. coli, leptospirosis, and pasteurella require vaccines that deliver robust mucosal and systemic protection, while parasitic infections involving ectoparasites or endoparasites often demand combination approaches and integrated pest management. Viral priorities include avian influenza, bovine viral diarrhea virus, foot-and-mouth disease virus, Newcastle disease virus, porcine reproductive and respiratory syndrome virus, and rabies virus, each presenting distinct antigenic variability and regulatory considerations. Route of administration is a critical commercial axis: injectable formulations, including intramuscular, intravenous, and subcutaneous approaches, remain predominant for many production species, whereas oral vaccines offer clear advantages for mass administration in poultry and wild or stray populations.
Finally, distribution dynamics differ by channel: online pharmacies, retail pharmacies, and veterinary clinics each play unique roles in reach, pricing, and post-sales engagement, and successful commercialization requires tailoring packaging, labeling, and service models to the dominant channel in a given region and species segment.
Comparative regional intelligence highlighting regulatory nuance, manufacturing priorities, and channel structures shaping vaccine adoption across global geographies
Regional dynamics exert a strong influence on regulatory timelines, supply chain design, and disease prioritization across the animal vaccines landscape. In the Americas, established regulatory frameworks, sizable companion animal markets, and mature veterinary practice networks create fertile conditions for high-value modalities and premium pricing models, while production-animal sectors emphasize scale, cost-effectiveness, and solutions that integrate with large farm operations.
In Europe, Middle East & Africa, heterogeneous markets drive a dual approach: high-regulation countries favor innovative platforms and stringent safety data, whereas resource-constrained markets in some regions require low-cost, thermostable solutions and flexible distribution strategies. Regional disease burdens, wildlife reservoirs, and cross-border trade considerations also shape prioritization in this geography. In the Asia-Pacific region, rapid agricultural modernization, significant poultry and swine production, and an expanding companion animal base have increased demand for both traditional and novel vaccines; regional manufacturing expansion and public-private partnerships are common strategies to manage scale and respond to emergent disease threats.
Across regions, alignment between local regulatory expectations, cold chain capabilities, and channel structures determines the optimal product profile and commercialization blueprint. Companies that tailor their product design and commercial model to these regional nuances will achieve greater penetration and long-term uptake.
How top animal healthcare organizations are aligning platform R&D, manufacturing partnerships, and commercial alliances to accelerate development and expand global reach
Leading organizations in the animal vaccines domain are investing heavily in platform diversification, supply chain resilience, and strategic partnerships to accelerate pipeline execution. Firms are extending internal capabilities through targeted collaborations with academic centers and biotech innovators to access advanced antigen design and adjuvant science, while contract manufacturing relationships are expanding to support fill/finish and cold chain-sensitive biologics. Strategic M&A, licensing deals, and co-development agreements are common tools used to acquire niche technologies, secure geographic access, and scale manufacturing rapidly in response to disease outbreaks.
Corporate R&D is increasingly organized around modular platforms that can be repurposed across multiple antigen targets, enabling more efficient regulatory submissions and faster post-approval lifecycle management. Companies are also prioritizing investments in analytics and real-world evidence systems to demonstrate long-term efficacy and safety, which supports veterinarian confidence and payer negotiations. On the commercial side, partnerships with distribution networks and channel-focused service providers help extend reach into underserved markets and improve compliance among animal owners.
Ultimately, organizations that combine deep scientific capability with flexible manufacturing footprints and robust commercial partnerships are best positioned to convert innovation into sustained market impact and to manage operational risk in a rapidly changing policy and trade environment.
Actionable strategic roadmap for leaders to align platform investments, regional manufacturing resilience, and channel-specific commercialization to capture sustainable value
Industry leaders should adopt a multi-pronged strategy that links scientific capability with operational flexibility and market-focused commercialization. First, prioritize investment in platform technologies that enable antigen modularity and faster candidate iteration, while ensuring parallel development of adjuvant and delivery systems that enhance durability and reduce dosing frequency. Second, design manufacturing footprints with regional redundancy and fill/finish capabilities to mitigate tariff and logistics risks; evaluate strategic partnerships with contract manufacturers to scale rapidly when outbreak response demands surge.
Third, integrate regulatory engagement early in development to align on evidence expectations for novel modalities and to explore platform-based review pathways where available. Fourth, tailor commercial models by species and channel: develop premium, convenience-oriented formats for companion animals sold through clinics and pharmacies, and pursue cost-optimized, mass-administration solutions for livestock that accommodate on-farm workflows. Fifth, invest in data ecosystems that combine surveillance, post-licensure safety monitoring, and economic value evidence to strengthen adoption narratives and support payer conversations.
By executing on these priorities, organizations can reduce time-to-adoption, protect margins against trade disruption, and position their portfolios to meet evolving animal health needs across diverse regions and species.
Transparent mixed-method research approach combining stakeholder interviews, technical literature review, and multi-source triangulation to ensure robust insights
The research underpinning this analysis integrates primary and secondary methods to ensure robustness and traceability. Primary research included structured interviews with industry executives, veterinarians, regulatory specialists, and supply chain operators to capture current practices, pain points, and near-term investment plans. These qualitative inputs were supplemented by technical reviews of peer-reviewed literature, regulatory guidance documents, and publicly disclosed corporate disclosures to ground scientific and policy assertions in verifiable sources.
Secondary analysis involved triangulation across multiple data streams to validate thematic trends and to identify cross-cutting risks and opportunities. Methodological safeguards included cross-validation of interview findings, scenario testing of supply chain responses to policy shifts, and expert review panels to assess the plausibility of technological adoption timelines. All conclusions were evaluated for practical relevance by commercial and scientific advisors to ensure they translate into operationally useful guidance.
This mixed-method approach balances depth and breadth, delivering insights that are both evidence-based and actionable for decision-makers responsible for R&D prioritization, manufacturing planning, and go-to-market execution in the animal vaccines sector.
Synthesis of strategic imperatives showing how innovation, regulatory engagement, and operational adaptability combine to drive sustainable outcomes in animal vaccines
The animal vaccines sector is entering a period of accelerated change driven by technological innovation, shifting regulatory attitudes, and evolving distribution dynamics. Platform technologies are expanding the horizon of what is scientifically feasible, while tariff and supply chain pressures are reshaping operational choices. Companies that synchronize scientific ambition with pragmatic manufacturing and channel strategies will create durable competitive advantage and better serve both companion and production animal health needs.
Sustained success will require organizations to adopt modular R&D approaches, build regional manufacturing resilience, and embed data-driven evidence generation into commercialization plans. Equally important is cultivating regulatory partnerships and channel-specific capabilities that reflect local market realities. In an environment where disease emergence and trade policy can rapidly alter the competitive landscape, flexibility and anticipatory planning are the most valuable assets.
This study provides a strategic lens for decision-makers seeking to balance innovation with operational rigor, and it highlights the concrete steps organizations can take to align scientific progress with commercial viability across species and regions.
Please Note: PDF & Excel + Online Access - 1 Year
A strategic introductory overview of evolving scientific advances, regulatory pressures, and commercialization imperatives shaping the animal vaccines ecosystem
The animal vaccines sector is at an inflection point driven by converging scientific progress, shifting animal health priorities, and evolving distribution channels. Advances in molecular biology and platform technologies are expanding the vaccine toolbox, while heightened attention to zoonotic risk and antimicrobial stewardship intensifies demand for preventive solutions. Investors, manufacturers, and veterinary stakeholders face a more complex landscape in which scientific feasibility, regulatory pathways, and supply chain robustness all influence product success.
Against this backdrop, decisions about pipeline prioritization and resource allocation require a clear view of where innovation is translating into adoption. Breakthroughs in nucleic acid technologies, recombinant antigen design, and adjuvant optimization are enabling faster development cycles and more targeted protection across companion and production species. At the same time, regulatory frameworks and animal owner willingness to pay differ by jurisdiction, creating differentiated commercialization pathways.
This report frames those dynamics, connecting scientific innovation to practical imperatives for commercialization. It emphasizes how integrated thinking across R&D, manufacturing, and distribution can shorten time-to-adoption and strengthen resilience to regulatory and trade disruptions. By clarifying these linkages, leaders can better align investments with the realities of a rapidly evolving animal health ecosystem.
How platform technologies, supply chain modernization, and regulatory adaptation are jointly accelerating innovation and market entry across the animal vaccines landscape
The past several years have produced transformative shifts that are redefining how animal vaccines are developed, manufactured, and delivered. Platform technologies such as mRNA and recombinant expression systems have reduced biological complexity for certain targets, enabling more agile responses to emergent viral threats and allowing developers to pursue antigen designs that were previously impractical. These scientific shifts are complemented by advances in adjuvant chemistry and delivery systems that improve durability of immune responses, especially in production animals where long-term protection drives economic value.
Simultaneously, the industry has seen a marked movement toward integrated supply chains and regional manufacturing hubs to mitigate logistical risk and reduce time-to-deployment. Digital tools for cold chain monitoring, remote veterinary diagnostics, and data-driven disease surveillance are improving vaccine targeting and post-marketing evidence generation. Regulatory pathways are adapting to novel modalities, with agencies increasingly open to platform-based review paradigms that can accelerate approval for subsequent constructs built on validated platforms.
Taken together, these trends are catalyzing a shift from incremental product updates to platform-centric strategies. Organizations that combine scientific depth with operational flexibility and strong regulatory engagement are positioned to capture the most value as adoption patterns evolve across companion and production animal segments.
Assessment of how 2025 tariff adjustments have reshaped sourcing decisions, regional manufacturing strategies, and commercial resilience across the value chain
The cumulative effect of trade policy changes implemented in 2025 has rippled across sourcing, pricing, and distribution choices for animal vaccine stakeholders. Tariff increases and adjustments to import classifications have raised the cost and complexity of importing finished biologics and certain raw materials, prompting many manufacturers to reassess cross-border supply strategies. In response, companies have accelerated regional sourcing, relocated critical component manufacturing closer to end markets, and expanded local fill/finish capabilities to preserve margin and ensure timely delivery.
These adaptations have also altered procurement strategies among distributors and veterinary providers. Buyers are placing greater emphasis on vendor diversification and contractual terms that protect against sudden cost escalation. In parallel, some firms are renegotiating supply agreements with raw material suppliers and contract manufacturing organizations to share risk and secure priority access to limited capacity. The combination of tariff-driven cost pressures and supply chain reconfiguration has elevated the strategic importance of manufacturing redundancy, inventory planning, and tariff-aware route-to-market designs.
Looking forward, stakeholders that proactively map tariff exposure across the product lifecycle, invest in regional manufacturing nodes where feasible, and cultivate flexible logistics options will be better positioned to maintain continuity of supply and protect commercial margins amid ongoing policy uncertainty.
In-depth segmentation analysis showing how product modalities, species-specific needs, disease targets, administration routes, and distribution channels interact to shape strategic choices
A granular segmentation lens reveals how product modality, animal species, disease target, administration route, and distribution channel each shape research priorities and commercial opportunity. Product innovation spans inactivated vaccines, live attenuated vaccines, mRNA vaccines, recombinant vaccines, and subunit vaccines, with modality choice influenced by pathogen biology, safety profile, and manufacturing scalability. Species differences matter: companion animal markets center on cats and dogs where owner willingness to invest in advanced modalities and convenience-driven formats is relatively high, while livestock markets focus on cattle, poultry, sheep, and swine where economic drivers and mass-administration logistics dominate adoption decisions.
Disease-specific targeting further refines strategy; bacterial infections such as clostridial disease, E. coli, leptospirosis, and pasteurella require vaccines that deliver robust mucosal and systemic protection, while parasitic infections involving ectoparasites or endoparasites often demand combination approaches and integrated pest management. Viral priorities include avian influenza, bovine viral diarrhea virus, foot-and-mouth disease virus, Newcastle disease virus, porcine reproductive and respiratory syndrome virus, and rabies virus, each presenting distinct antigenic variability and regulatory considerations. Route of administration is a critical commercial axis: injectable formulations, including intramuscular, intravenous, and subcutaneous approaches, remain predominant for many production species, whereas oral vaccines offer clear advantages for mass administration in poultry and wild or stray populations.
Finally, distribution dynamics differ by channel: online pharmacies, retail pharmacies, and veterinary clinics each play unique roles in reach, pricing, and post-sales engagement, and successful commercialization requires tailoring packaging, labeling, and service models to the dominant channel in a given region and species segment.
Comparative regional intelligence highlighting regulatory nuance, manufacturing priorities, and channel structures shaping vaccine adoption across global geographies
Regional dynamics exert a strong influence on regulatory timelines, supply chain design, and disease prioritization across the animal vaccines landscape. In the Americas, established regulatory frameworks, sizable companion animal markets, and mature veterinary practice networks create fertile conditions for high-value modalities and premium pricing models, while production-animal sectors emphasize scale, cost-effectiveness, and solutions that integrate with large farm operations.
In Europe, Middle East & Africa, heterogeneous markets drive a dual approach: high-regulation countries favor innovative platforms and stringent safety data, whereas resource-constrained markets in some regions require low-cost, thermostable solutions and flexible distribution strategies. Regional disease burdens, wildlife reservoirs, and cross-border trade considerations also shape prioritization in this geography. In the Asia-Pacific region, rapid agricultural modernization, significant poultry and swine production, and an expanding companion animal base have increased demand for both traditional and novel vaccines; regional manufacturing expansion and public-private partnerships are common strategies to manage scale and respond to emergent disease threats.
Across regions, alignment between local regulatory expectations, cold chain capabilities, and channel structures determines the optimal product profile and commercialization blueprint. Companies that tailor their product design and commercial model to these regional nuances will achieve greater penetration and long-term uptake.
How top animal healthcare organizations are aligning platform R&D, manufacturing partnerships, and commercial alliances to accelerate development and expand global reach
Leading organizations in the animal vaccines domain are investing heavily in platform diversification, supply chain resilience, and strategic partnerships to accelerate pipeline execution. Firms are extending internal capabilities through targeted collaborations with academic centers and biotech innovators to access advanced antigen design and adjuvant science, while contract manufacturing relationships are expanding to support fill/finish and cold chain-sensitive biologics. Strategic M&A, licensing deals, and co-development agreements are common tools used to acquire niche technologies, secure geographic access, and scale manufacturing rapidly in response to disease outbreaks.
Corporate R&D is increasingly organized around modular platforms that can be repurposed across multiple antigen targets, enabling more efficient regulatory submissions and faster post-approval lifecycle management. Companies are also prioritizing investments in analytics and real-world evidence systems to demonstrate long-term efficacy and safety, which supports veterinarian confidence and payer negotiations. On the commercial side, partnerships with distribution networks and channel-focused service providers help extend reach into underserved markets and improve compliance among animal owners.
Ultimately, organizations that combine deep scientific capability with flexible manufacturing footprints and robust commercial partnerships are best positioned to convert innovation into sustained market impact and to manage operational risk in a rapidly changing policy and trade environment.
Actionable strategic roadmap for leaders to align platform investments, regional manufacturing resilience, and channel-specific commercialization to capture sustainable value
Industry leaders should adopt a multi-pronged strategy that links scientific capability with operational flexibility and market-focused commercialization. First, prioritize investment in platform technologies that enable antigen modularity and faster candidate iteration, while ensuring parallel development of adjuvant and delivery systems that enhance durability and reduce dosing frequency. Second, design manufacturing footprints with regional redundancy and fill/finish capabilities to mitigate tariff and logistics risks; evaluate strategic partnerships with contract manufacturers to scale rapidly when outbreak response demands surge.
Third, integrate regulatory engagement early in development to align on evidence expectations for novel modalities and to explore platform-based review pathways where available. Fourth, tailor commercial models by species and channel: develop premium, convenience-oriented formats for companion animals sold through clinics and pharmacies, and pursue cost-optimized, mass-administration solutions for livestock that accommodate on-farm workflows. Fifth, invest in data ecosystems that combine surveillance, post-licensure safety monitoring, and economic value evidence to strengthen adoption narratives and support payer conversations.
By executing on these priorities, organizations can reduce time-to-adoption, protect margins against trade disruption, and position their portfolios to meet evolving animal health needs across diverse regions and species.
Transparent mixed-method research approach combining stakeholder interviews, technical literature review, and multi-source triangulation to ensure robust insights
The research underpinning this analysis integrates primary and secondary methods to ensure robustness and traceability. Primary research included structured interviews with industry executives, veterinarians, regulatory specialists, and supply chain operators to capture current practices, pain points, and near-term investment plans. These qualitative inputs were supplemented by technical reviews of peer-reviewed literature, regulatory guidance documents, and publicly disclosed corporate disclosures to ground scientific and policy assertions in verifiable sources.
Secondary analysis involved triangulation across multiple data streams to validate thematic trends and to identify cross-cutting risks and opportunities. Methodological safeguards included cross-validation of interview findings, scenario testing of supply chain responses to policy shifts, and expert review panels to assess the plausibility of technological adoption timelines. All conclusions were evaluated for practical relevance by commercial and scientific advisors to ensure they translate into operationally useful guidance.
This mixed-method approach balances depth and breadth, delivering insights that are both evidence-based and actionable for decision-makers responsible for R&D prioritization, manufacturing planning, and go-to-market execution in the animal vaccines sector.
Synthesis of strategic imperatives showing how innovation, regulatory engagement, and operational adaptability combine to drive sustainable outcomes in animal vaccines
The animal vaccines sector is entering a period of accelerated change driven by technological innovation, shifting regulatory attitudes, and evolving distribution dynamics. Platform technologies are expanding the horizon of what is scientifically feasible, while tariff and supply chain pressures are reshaping operational choices. Companies that synchronize scientific ambition with pragmatic manufacturing and channel strategies will create durable competitive advantage and better serve both companion and production animal health needs.
Sustained success will require organizations to adopt modular R&D approaches, build regional manufacturing resilience, and embed data-driven evidence generation into commercialization plans. Equally important is cultivating regulatory partnerships and channel-specific capabilities that reflect local market realities. In an environment where disease emergence and trade policy can rapidly alter the competitive landscape, flexibility and anticipatory planning are the most valuable assets.
This study provides a strategic lens for decision-makers seeking to balance innovation with operational rigor, and it highlights the concrete steps organizations can take to align scientific progress with commercial viability across species and regions.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
192 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rapid adoption of mRNA and DNA vaccine platforms to tackle emerging zoonotic threats
- 5.2. Growing integration of autogenous vaccines to address farm-specific pathogen outbreaks in swine herds
- 5.3. Increased use of DIVA vaccine strategies for differentiating infected from vaccinated animals in avian flu control
- 5.4. Advances in nanoparticle adjuvants enhancing immunogenicity of equine influenza vaccines across global markets
- 5.5. Emergence of combination vaccines targeting multiple clostridial and bacterial pathogens in ruminant livestock health
- 5.6. Expansion of regulatory frameworks supporting conditional approval of emergency animal vaccines during disease outbreaks
- 5.7. Implementation of precision livestock vaccination programs powered by farm data analytics and IoT monitoring devices
- 5.8. Surge in demand for single-dose sustained-release formulations optimizing labor and compliance in poultry immunization
- 5.9. Strategic partnerships between biotech firms and veterinary service providers for vaccine distribution in remote regions
- 5.10. Development of thermostable vaccine formulations reducing cold chain dependency in tropical livestock markets
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Animal Vaccines Market, by Product
- 8.1. Inactivated Vaccines
- 8.2. Live Attenuated Vaccines
- 8.3. mRNA Vaccines
- 8.4. Recombinant Vaccines
- 8.5. Subunit Vaccines
- 9. Animal Vaccines Market, by Animal Type
- 9.1. Companion Animals
- 9.1.1. Cats
- 9.1.2. Dogs
- 9.2. Livestock Animals
- 9.2.1. Cattle
- 9.2.2. Poultry
- 9.2.3. Sheep
- 9.2.4. Swine
- 10. Animal Vaccines Market, by Disease Type
- 10.1. Bacterial Infections
- 10.1.1. Clostridial
- 10.1.2. E. Coli
- 10.1.3. Leptospirosis
- 10.1.4. Pasteurella
- 10.2. Fungal Infections
- 10.3. Parasitic Infections
- 10.3.1. Ectoparasites
- 10.3.2. Endoparasites
- 10.4. Viral Infections
- 10.4.1. Avian Influenza Virus
- 10.4.2. Bovine Viral Diarrhea Virus (BVDV)
- 10.4.3. Foot-and-Mouth Disease Virus (FMDV)
- 10.4.4. Newcastle Disease Virus
- 10.4.5. Porcine Reproductive & Respiratory Syndrome Virus (PRRSV)
- 10.4.6. Rabies Virus
- 11. Animal Vaccines Market, by Route of Administration
- 11.1. Injectable Vaccines
- 11.1.1. Intramuscular (IM)
- 11.1.2. Intravenous (IV)
- 11.1.3. Subcutaneous (SC)
- 11.2. Oral Vaccines
- 12. Animal Vaccines Market, by Distribution Channel
- 12.1. Online Pharmacies
- 12.2. Retail Pharmacies
- 12.3. Veterinary Clinics
- 13. Animal Vaccines Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Animal Vaccines Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Animal Vaccines Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Biogénesis Bagó S.A.
- 16.3.2. BioVaxys Technology Corporation
- 16.3.3. Boehringer Ingelheim International GmbH
- 16.3.4. Brilliant Bio Pharma Private limited
- 16.3.5. Ceva Santé Animale
- 16.3.6. China Animal Husbandry Industry Co., Ltd.
- 16.3.7. Dalan Animal Health
- 16.3.8. Elanco Animal Health Inc.
- 16.3.9. Endovac Animal Health, LLC by Immvac Inc.
- 16.3.10. Hester Biosciences Limited
- 16.3.11. HIPRA, S.A.
- 16.3.12. Indian Immunologicals Limited
- 16.3.13. Kemin Industries, Inc.
- 16.3.14. Merck KGaA
- 16.3.15. Neogen Corporation
- 16.3.16. Phibro Animal Health Corporation
- 16.3.17. SAN Vet Holding GmbH
- 16.3.18. Sanofi S.A.
- 16.3.19. Seppic S.A.
- 16.3.20. Torigen Pharmaceuticals Inc.
- 16.3.21. Vaxxinova GmbH
- 16.3.22. VEROVACCiNES GmbH
- 16.3.23. Vetigenics, LLC
- 16.3.24. Vetoquinol SA
- 16.3.25. Virbac, Inc.
- 16.3.26. Zoetis Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
